Published in AIDS Weekly, February 1st, 1999
The most deadly opportunistic infection among western AIDS patients is Pneumocystis carinii pneumonia (PCP). Trimethoprim-sulfamethoxazole (TMP/SMX; cotrimoxazole) is the drug combination of choice for PCP prevention. It is recommended for all HIV infected patients when their T-cell counts fall below 200 cells/(mu)L.
But can PCP prophylaxis be discontinued when T cell counts rise above 200 cells/(mu)L in patients receiving highly active antiretroviral therapy (HAART) regimens' The cautious answer, based on early follow-up data, is yes.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.